Ipca Laboratories has reported results for first quarter ended June 30, 2012.
The company has reported decline of 30.31% in its net profit at Rs 42.98 crore for the quarter under review as compared to Rs 61.67 crore for the same quarter in the previous year. However, the total income from operation of the company has increased by 19.72% at Rs 634.40 crore for Q1FY13 as compared Rs 529.90 crore for the corresponding quarter previous year.
Ipca Laboratories is engaged in manufacturing of active pharmaceutical ingredients and formulations. It operates in 110 countries and its export accounts for 50% of the company’s income. Worldwide the company is one of the largest suppliers of APIs and intermediates. The company holds leadership position in Anti-malarial and Rheumatoid Arthritis area.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1532.85 |
Dr. Reddys Lab | 5812.50 |
Cipla | 1403.90 |
Zydus Lifesciences | 1104.45 |
Lupin | 1661.90 |
View more.. |